Supplementation of dietary semen vaccariae extracts to lactating sow diets: effects on the production performance, milk components, and gene expression related to mammogenesis.

This study aimed to investigate the effects of dietary semen vaccariae extracts (SVE) on the production performance, colostrum components, and relative gene expression related to mammogenesis of lactating sows. 48 pregnant sows were selected and randomly allocated into four groups, with six replicates and two sows per replicate. The first group was the control (CON), while the other groups received the same diet further supplemented with 1.5, 3.0 and 4.5 g SVE per kg (SV1, SV2 and SV3, respectively). Compared with the control group, (1) the average daily gain was increased (p < 0.05) in SV1, SV2, and SV3 during the 11-21 days and 1-21 days of lactation; (2) the serum insulin-like growth factor-1, insulin, prolactin, and estrogen contents in SV1, SV2, and SV3 were increased (p < 0.05) on the 1st and 21st day of lactation; (3) The plasma Lysine, Threonine, and Tryptophan concentrations were also higher (p < 0.05) in SV1, SV2, and SV3 on the 1st and 21st day of lactation; (4) The milk Lysine, Methionine, Threonine, and Tryptophan concentrations were higher (p < 0.05) in SV1, SV2, and SV3 on the 1st and 21st day of lactation; (5) The milk lactose ratio and milk protein content were increased (p < 0.05) in the groups treated with semen vaccariae on the 1st day of lactation, while the milkfat ratio and milk protein content were increased (p < 0.05) in SV2 and SV3 on the 21st day of lactation; (6) the immunoglobulin M, A, and G contents were increased (p < 0.05) in the groups treated with the semen vaccariae on the first day of lactation; and (7) the relative PRLR, STAT5a, FcRn, CSN2, and LALBA expressions were higher (p < 0.05) in the groups treated with the semen vaccariae on the 1st and 21st day of lactation. In this study, the optimum dosage was 3.0 g/kg semen vaccariae, which increased the average daily gain of piglets, total lactation yield, and serum hormone levels, improved the amino acid levels in plasma, and facilitated the milk quality, up-regulated the relative gene expressions in the mammogenesis.

Biodegradable Imprinted Polymer Based on ZIF-8/DOX-HA for Synergistically Targeting Prostate Cancer Cells and Controlled Drug Release with Multiple Responses.

Improving the drug loading and delivery efficiency of biodegradable nanomaterials used for targeting prostate cancer (PCa) remains a challenging task. To accomplish this task, herein, a new surface molecularly imprinted polymer (ZIF-8/DOX-HA@MIP) was designed and constructed with a hyaluronic acid (HA)-modified zeolitic imidazolate framework-8 (ZIF-8) metal-organic framework loaded with doxorubicin (DOX) as a substrate and a responsive molecularly imprinted polymer film as a shell. Owing to the large surface area of ZIF-8, DOX was successfully loaded into the ZIF-8/DOX-HA@MIP with a high drug loading efficiency (more than 88%). In vitro cell experiments have shown that the strengthened targeting ability of ZIF-8/DOX-HA@MIP to PCa cells was realized through the synergistic effect of HA and the molecularly imprinted membrane. Under the condition of simulated tumor microenvironment solution, Zn species were released and the particle size of ZIF-8/DOX-HA@MIP decreased gradually by the synergistic effect of hyaluronidase, pH, and glutathione, showing excellent biodegradability. In vivo antitumor research indicated the excellent antitumor activity and biocompatibility of ZIF-8/DOX-HA@MIP. The multifunctional ZIF-8/DOX-HA@MIP constructed herein provides a novel impetus for the development of targeted drug delivery in PCa treatment and a new strategy for treating other tumors.

Disulfide-Bridged Dendritic Organosilicas-Based Biodegradable Molecularly Imprinted Polymers for Multiple Targeting and pH/Redox-Responsive Drug Release toward Chemical/Photodynamic Synergistic Tumor Therapy.

In this study, a sialic acid (SA) and transferrin (TF) imprinted biodegradable disulfide bridging organosilicas-based drug delivery system (SS-DMONS/DOX-Ce6@MIPs) for targeted cancer therapy is constructed, for the first time. Disulfide bridged dendritic mesoporous organosilicas nanoparticles (SS-DMONs) not only enhance drug loading as the drug repository, but also provide enough specific surface area for the molecular imprinting shell to expose more degradation and imprinted sites on the surface. In addition, SS can be disturbed in a highly reducing tumor microenvironment to achieve degradation. The biodegradable imprinting film, prepared with customized 2-amino-N-(3,4-dihydroxyphenethyl)-3-mercaptopropanamide and 4-mercaptophenylboronic acid as functional monomers, endows SS-DMONs with active targeting capacity, and responsive drug release through degradation under acidic and highly reductive tumor microenvironment. SS-DMONS/DOX-Ce6@MIPs after binding of TF can target tumor cells actively through multiple interactions, including the affinity between antigen and antibody, and the specific recognition between molecularly imprinted polymers and template molecules. Under laser irradiation the loaded chlorin e6 (Ce6) that can produce toxic reactive oxygen, combined with the doxorubicin (DOX), achieves chemical/photodynamic synergistic anticancer effects. SS-DMONS/DOX-Ce6@MIPs present excellent tumor targeting and dual-responsive drug release, which provides an effective strategy for chemical/photodynamic antitumor therapy.

A molecularly imprinted photopolymer based on mesh TpPa-2 embedded with perovskite CsPbBr3 quantum dots for the sensitive solid fluorescence sensing of patulin in apple products.

Here, a novel molecularly imprinted photopolymer was prepared using CsPbBr3 quantum dots as the fluorescence source, TpPa-2 as substrate for selective solid fluorescence detection of patulin (PAT). TpPa-2 can promote efficient recognition of PAT due to its unique structure and significantly improve the fluorescence stability and sensitivity. The test results showed that the photopolymer exhibited large adsorption capacity (131.75 mg/g), fast adsorption ability (12 mins), superior reusability and high selectivity. The sensor proposed had good linearity for PAT in the range of 0.2-20 ng/mL and was applied to the analysis of PAT in apple juice and apple jam with a limit of detection as low as 0.027 ng/mL. Therefore it maybe a promising method for solid fluorescence detection of trace PAT in food analysis.

Biodegradable magnesium ion-doped silica-based molecularly imprinted nanoparticles for targeting tumor cells to drugs controlled release and recognition mechanism research.

Herein, we designed and constructed a novel biodegradable molecularly imprinted nanoparticles (Mg-SMSNs/DOX-Ce6 @MIPs) using a new degradable functional monomer prepared by glycerol and lactide, on magnesium ion-doped stellated mesoporous silica nanoparticles (Mg-SMSNs). These nanoparticles loaded with the anticancer drug doxorubicin (DOX) and chlorin e6 (Ce6) were used to target sialic acid (SA) overexpressed on the surface of tumor cells and release drugs in response to the tumor microenvironment. The molecularly imprinted layer avoided premature drug leakage, meanwhile, the large number of ester bonds contained in the functional monomers in the layer degraded by protonation in the tumor microenvironment to expose the drugs. Mg2+ doping in SMSNs enhanced the degradation performance in tumor microenvironment to achieve tumor-responsive drug release. The multifunctional monomers increased the interaction with SA, enhanced the binding force, and accurately targeted recognition was obtained. The recognition mechanism of Mg-SMSNs/DOX-Ce6 @MIPs to SA and drug release were investigated by model analysis. The cytotoxicity and cellular targeting of Mg-SMSNs/DOX-Ce6 @MIPs revealed that Mg-SMSNs/DOX-Ce6 @MIPs could specifically recognize SA to target MCF-7 tumor cells without interference. Under laser irradiation, Ce6 and DOX could achieve synergistic treatment to tumor cells. Mg-SMSNs/DOX-Ce6 @MIPs present good biological abilities in terms of active targeting, pH-responsiveness, antitumor efficiency and biocompatibility.